FDA to review udenafil for use in single ventricle disease
Udenafil, a novel phosphodiesterase-5 inhibitor, is currently under investigation for use to improve symptoms in patients after a palliative Fontan procedure. The FDA granted orphan designation for this treatment previously.
Source:
Biospace Inc.